Eotaxin, an inducer of eosinophil migration and activation, exerts its activity by binding to CCR3, the C-C chemokine receptor 3. An inhibitor of the eotaxin-CCR3 binding interaction may have potential as an anti-inflammatory drug for treatment of asthma, parasitic infections, and allergic disorders. A radioligand binding assay was developed using HEK cells transfected with CCR3, with 125I eotaxin as the ligand. Whole cells grown on polylysine-coated plates were used as the receptor source for the screen. Screening of more than 200,000 compounds with this assay yielded a number of screening hits, and of these, 2 active novel antagonists were identified. These compounds showed inhibitory effects on eosinophil chemotaxis in both in vitro and in vivo assays. (Journal of Biomolecular Screening 2003:324-331)
References
1.
1. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, et al: Eosinophilic inflammation in asthma . N Engl J Med1990;323(15): 1033-1039 .
3. Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ: Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways . J Allergy Clin Immunol2001;107(3): 469-476 .
4.
4. Griffiths-Johnson DA, Collins PD, Rossi AG, Jose PJ, Williams TJ: The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo . Biochem Biophys Res Commun1993;197(3): 1167-1172 .
5.
5. Ponath PD, Qin S, Post TW, Wang J, Wu L, Gerard NP, et al: Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils . J Exp Med1996;183: 2437-2448 .
6.
6. Heath H, Qin S, Rao P, Wu L, LaRosa G, Kassam N, et al: Chemokine receptor usage by human eosinophils: the importance of CCR3 demonstrated using an antagonistic monoclonal antibody . J Clin Invest1997;99(2): 178-184 .
7.
7. Uguccioni M, Mackay CR, Ochensberger B, Loetscher P, Rhis S, LaRosa GJ, et al: High expression of the chemokine receptor CCR3 in human blood basophils: role in activation by eotaxin, MCP-4, and other chemokines . J Clin Invest1997;100: 1137-1143 .
8.
8. Romagnani P, De Paulis A, Beltrame C, Annunziato F, Dente V, Maggi E, et al: Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines . Am J Pathol1999;155: 1195-1204 .
9.
9. Gerber BO, Zanni MP, Uguccioni M, Loetscher M, Mackay CR, Pichler WJ, et al: Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils . Curr Biol1997;7: 836-843 .
10.
10. Sallusto F, Mackay CR, Lanzavecchia A: Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells . Science1997;277: 2005-2007 .
11.
11. Van Acker FAA, Voss H-P, Timmerman HC: Chemokines structure, receptors and functions: a new target for inflammation and asthma therapy . Mediators of Inflammation1996;5: 393-416 .
12.
12. Bryan SA, Jose PJ, Topping JR, Wilhelm R, Soderberg C, Kertez D, et al: Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists . Am J Respir Crit Care Med2002;165(12): 1602-1609 .
13.
13. Lucca GV, Kim UT, Johnson C, Vargo BJ, Welch PK, Covington M, et al: Discovery and structure-activity relationship of N-(uredoalkyl)-benzylpiperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists . J Med Chem2002;45: 3794-3804 .
14.
14. Wacker DA, Santella JB III, Gardner DS, Varnes JG, Estrella M, DeLucca GV, et al: CCR3 antagonists: a potential new therapy for the treatment of asthma: discovery and structure-activity relationships . Bioorg Med Chem Lett2002;12(13): 1785-1789 .
15.
15. White JR, Lee JM, Dede K, Imburgia CS, Jurewicz AJ, Chan GM, et al: Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4- induced eosinophil migration . J Biol Chem2000;275: 36626-36631 .
16.
16. Saeki T, Ohwaki K, Naya A, Kobayashi K, Ishikawa M, Ohtake N, et al: Identification of a potent and nonpeptidyl CCR3 antagonist . Biochem Biophys Res Commun2001;281(3): 779-782 .
17.
17. Sabroe I, Peck MJ, Van Keulen BJ, Jorritsma A, Simmons G, Clapham PR, et al: A small molecule antagonist of chemokine receptors CCR1 and CCR3: potent inhibition of eosinophil function and CCR3 mediated HIV entry . J Biol Chem2000;275(34): 25985-25992 .
18.
18. Sheets MP, Warrior U, Yoon H, Mollison KW, Djuric SW, Trevillyan JM: A high capacity scintillation proximity assay for the discovery and evaluation of ZAP-70tandemSH2 domain antagonists . J Biomol Screen1998;3: 139-144 .
19.
19. Zhang J-H, Chung TDY, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening . J Biomol Screen1999;4: 67-73 .
20.
20. Harris RR, Komater VA, Marett RA, Wilcox DM, Bell RL: The effect of mast cell deficiency and leukotriene inhibition on the influx of eosinophils induced by eotaxin . J Leuko Biol1997;62: 688-691 .
